Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00779311 · ClinicalTrials.gov registry record · Phase 1
A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Accelerated Community Oncology Research Network.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00779311 is a Phase 1 study that was terminated before completion, run by Accelerated Community Oncology Research Network. The registered enrollment target is 8 participants.
The verdict
NCT00779311, a Phase 1 study, was terminated before completion, sponsored by Accelerated Community Oncology Research Network.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This research study is being performed at approximately 3 sites associated with Accelerated Community Oncology Research Network, Inc. (ACORN). Approximately 45 subjects will take part in this study. In this study, everyone will receive the same dose of mFOLFOX6 and Avastin. There will be five groups of subjects. Each group of subjects will receive a higher dose of Nexavar than the previous group. This will continue until a subject group has a major side effects from the dose they are given. This is so that the sponsor can determine the highest dose of Nexavar that can be used with mFOLFOX6 and AVastin (this is called the maximum tolerated dose or MTD).
Interventions
- DRUG sorafenib
- DRUG bevacizumab
- DRUG mFOLFOX6 regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00779311
The ClinicalTrials.gov registry entry for NCT00779311 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Accelerated Community Oncology Research Network, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which sorafenib is the first listed.
NCT00779311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00779311 about?
NCT00779311 is a clinical study titled "A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer". This research study is being performed at approximately 3 sites associated with Accelerated Community Oncology Research Network, Inc. (ACORN). Approximately 45 subjects will take part in this study. In this study, everyone will receive the same dose of mFOLFOX6 and Avastin. There will be five group...
What is the current status of trial NCT00779311?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2008-10. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00779311?
The interventions under investigation include: sorafenib (DRUG), bevacizumab (DRUG), mFOLFOX6 regimen (DRUG).
Who is sponsoring clinical trial NCT00779311?
This trial is sponsored by Accelerated Community Oncology Research Network, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.